.jpg "LivaNova PLC (NASDAQ: LIVN)")
In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on LivaNova PLC (NASDAQ: LIVN). The company’s shares closed yesterday at $83.32.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.9% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.
Currently, the analyst consensus on LivaNova PLC is Moderate Buy and the average price target is $98.75, representing a 18.5% upside.
In a report released yesterday, Canaccord Genuity also maintained a Hold rating on the stock with a $83 price target.
Find more picks by Best Performing Analysts >>
The company has a one-year high of $92.31 and a one-year low of $50.10. Currently, LivaNova PLC has an average volume of 421.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company specializing in the areas of Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management. It provides its services to patients, healthcare professionals and healthcare systems. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.
